GLP and Beyond: The Integrated Management System for Non-Clinical R&D Laboratories

In non-clinical research, the stakes are unforgiving. A safety study that cannot be reconstructed is a study that never happened — regulators will reject it, sponsors will not pay for it, and years of scientific work can evaporate over a gap in the raw data. That is why Good Laboratory Practice (GLP) exists, and why the most capable R&D laboratories go further, layering internationally recognized competence standards on top of GLP's study-integrity discipline. This guide explores the integrated management system (IMS) approach for non-clinical R&D laboratories — combining OECD GLP Principles, FDA 21 CFR Part 58, ISO/IEC 17025, ISO 15189, and ISO 9001 into one rigorously controlled framework. It is written for Study Directors, QA managers, CRO executives, and laboratory leaders preparing for regulatory inspection.

What is this integrated framework?

At its core sits Good Laboratory Practice — the quality system for non-clinical health and environmental safety studies. Two regulatory expressions dominate globally: the OECD Principles of GLP, applied through national monitoring authorities and underpinning the mutual acceptance of data across member countries, and the US FDA's 21 CFR Part 58, governing non-clinical laboratory studies supporting FDA submissions. Both share the same architecture: accountable Study Directors, approved study plans, standard operating procedures, characterized test items, faithful raw-data capture, secure archiving, and an independent Quality Assurance function that inspects studies and audits reports.

The integrated management system builds outward from that GLP core. ISO/IEC 17025 adds the technical-competence machinery — method validation, measurement traceability, and uncertainty — that gives analytical and bioanalytical work its scientific defensibility. ISO 15189 contributes clinically oriented laboratory quality practice where examinations touch biological materials. ISO 9001 wraps the whole in a management framework of leadership, risk-based thinking, and continual improvement. The result is a single system engineered for one purpose above all: regulatory study integrity.

Who needs it?

This IMS is built for non-clinical research and development laboratories conducting safety and regulatory studies, including:

• Contract research organizations (CROs) running toxicology, safety pharmacology, and environmental fate studies for sponsors
• Toxicology and bioanalytical laboratories generating data for regulatory submissions
• R&D facilities within pharmaceutical, agrochemical, and chemical companies preparing for GLP monitoring-authority inspection
• Laboratories facing study-sponsor audits who must demonstrate data integrity and independent QA
• Multi-disciplinary sites that also hold or seek ISO/IEC 17025 accreditation for analytical scopes

The commercial logic is blunt: regulatory authorities only accept safety data from facilities that demonstrate GLP compliance, and sponsors only place studies with laboratories that will survive inspection. A robust IMS is not overhead — it is the licence to operate.

Key benefits of the integrated approach

• Study validity protected — systematized study conduct and data integrity mean every study can be reconstructed, defended, and accepted.
• Inspection readiness — documentation and records organized the way monitoring authorities and sponsor auditors actually look for them.
• Faster data acceptance — credible GLP compliance accelerates the regulatory acceptance of submissions built on your data.
• One framework, many obligations — OECD GLP, FDA Part 58, and ISO requirements are satisfied through one coherent system instead of parallel bureaucracies.
• Competitive and scientific advantage — sponsors reward laboratories whose compliance record removes risk from their programmes.

What's inside the management system?

This is the deepest documentation architecture in the laboratory world, and the IMS covers it end to end:

• GLP study lifecycle governance — study plans and protocols, amendments and deviations, Study Director and Principal Investigator responsibilities, and personnel accountability throughout.
• Test-item control — characterization, receipt, handling, storage, and accountability of test and reference items.
• Standard operating procedures — an exceptionally deep SOP library governing facilities, equipment, test systems, data recording, and study conduct.
• Raw-data capture and traceability — controls enforcing attributable, legible, contemporaneous, original, and accurate records, with full chain-of-custody.
• Archiving — indexed, secure retention of study records, specimens, and reports under an accountable archivist.
• Independent Quality Assurance — a QA programme, independent of study conduct, delivering the study-based, facility-based, and process-based inspections and the final-report audits that GLP demands.
• Final report certification — Study Director claims of GLP compliance backed by QA statements.
• Technical competence layers — ISO/IEC 17025 and ISO 15189 procedures adding validation, traceability, and uncertainty rigour for analytical and bioanalytical work.
• Management-system elements — a master Quality Manual and compliance scheme mapping every principle to a control, plus internal audit, corrective action, management review, and training modules that build and document the competencies of Study Directors, technicians, and QA staff.
• Inspection-mirroring checklists — tools structured to match regulatory inspection modules, so self-assessment mirrors the real thing.

How the requirements fit together

Think of the framework in three concentric rings. The inner ring is the study: plan, conduct, raw data, report — governed by GLP's roles and records. The middle ring is the facility: equipment, test systems, SOPs, archives, and personnel competence — where ISO/IEC 17025 and ISO 15189 discipline the technical work. The outer ring is management: ISO 9001-style leadership, risk management, audit, and review, with independent QA cutting across all three rings as the internal regulator. A compliance scheme maps each OECD GLP Principle and each Part 58 provision to its controlling document, giving inspectors a direct clause-to-evidence trail.

The road to GLP recognition

1. Gap analysis — assess facilities, personnel, SOPs, data practices, and QA against OECD GLP, FDA Part 58, and applicable ISO requirements.
2. System construction — implement the Quality Manual, SOP library, study-document templates, and QA programme; appoint and train Study Directors and the archivist.
3. Pilot studies under GLP — conduct studies under the full system, generating the records inspectors will examine.
4. Internal inspections and audits — QA runs study, facility, and process inspections; management reviews the results.
5. Monitoring-authority inspection — the national GLP compliance monitoring authority inspects the facility and audits studies; FDA inspection applies for Part 58 scopes.
6. Corrective action and compliance status — findings are resolved; the facility enters the GLP compliance programme, with periodic re-inspection.
7. Parallel ISO/IEC 17025 accreditation — where analytical scopes warrant it, the accreditation body assesses and grants accreditation, with its own surveillance cycle.

How AGS can help

Very few laboratory teams have the bandwidth to author a GLP-grade documentation system while running live studies. The AGS IMS for Non-Clinical R&D Laboratories — a Tier 4 toolkit and the most extensive in our catalog — delivers the complete framework ready to deploy: a master Quality Manual and compliance scheme, an exceptionally deep library of editable procedures and forms enforcing traceable, reconstructable data, inspection-mirroring checklists, structured training modules, and compliance matrices mapping every GLP principle and ISO requirement to its control.

Every document is fully editable to your study types, test systems, and facilities. By systematizing study conduct, data integrity, and independent QA, the toolkit protects study validity, stands up to regulatory scrutiny, and accelerates the acceptance of your data in submissions. For laboratories whose science must survive the world's toughest inspections, AGS turns GLP compliance into what it should be — a durable competitive and scientific advantage.

View the toolkit →